Defense Advanced Research Projects Agency Extends Contract with AnaptysBio, Inc. to Generate Additional High Affinity Thermally Stable Antibodies

SAN DIEGO--(BUSINESS WIRE)--AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced that the Defense Advanced Research Projects Agency (DARPA) has extended its contract with AnaptysBio to generate additional high affinity thermally stable antibodies for biodefense applications. This extension was awarded based upon the successful completion by AnaptysBio of milestones during the first year of the contract.

Back to news